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CD4, CD8 and MHC Class I Expression in 
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ABSTRACT
Aim: The exact immunopathogenesis of Epstein-Barr virus (EBV)-
associated nasopharyngeal carcinoma (NPC) remains unclear. The aim 
of the present study was to assess the expression of CD4, CD8, and 
MHC class I molecules in NPC. 
Method: Biopsies were obtained from patients with NPC as well 
as the Epstein Barr virus (EBV)-seronegative patients as a control. 
Nasopharyngeal carcinoma patients were classified using the World 
Health Organization (WHO) pathological assessment and clinical stag-
ing of NPC.  The expression of CD4, CD8, and MHC class I in the biop-
sies were assessed immunohistochemically.  
Result: The results showed that  the number of CD4 positive, CD8 pos-
itive, and MHC class I positive cells  in NPC patients were higher than 
those in EBV-negative subjects (p<0.05). The number of these positive 
cells in NPC patients with WHO Type II or early clinical stage was not 
significantly differences with those with WHO Type III or late clinical 
stage, respectively (p>0.05).  No statistical differences between the 
number of CD4 positive and CD8 positive cells in NPC patients could 
be found (p>0.05). 
Conclusion: The results of the present study suggest, therefore, that 
the expression of CD4, CD8 and MHC class I molecules may not be as-
sociated with the pathologic classification and clinical staging of NPC 
and that the CD4:CD8 ratio in nasopharyngeal carcinoma may indicate 
decreased functions of these infiltrating T cell subsets.  
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INTRODUCTION
Nasopharyngeal carcinoma (NPC) is a tumor of epider-
moid origin and prevalent in several regions around the 
world.  Based on the degree of differentiation, the World 
Health Organization (WHO) classifies  NPC into keratin-
izing squamous cell carcinoma (WHO Type I) and nonke-
ratinizing carcinoma which is further subdivided into the 
differentiated subtype (WHO Type II) and undifferenti-
ated subtype (WHO Type III). The association between 
Epstein-Barr virus (EBV) and NPC is well known as shown 
by the fact that the EBV genome was found in the NPC 
speciments (1,2). However, it would appear that EBV is 
much more strongly associated with the undifferentiated 
NPC as compared with other NPC subtypes (3). EBV is a 
member of the herpesvirus family and primarily infects 
and replicates in the stratified squamous epithelium of 
oropharynx  (1,2).    
The precise pathogenesis by which EBV induces the de-
velopment of NPC remains to be further elucidated.  Both 
CD4+ and CD8+T cells have been shown to infiltrate in 
the stroma of NPC (4,5). Altered expression of major 
histocompatibility complex (MHC) class I has also been 
reported (5). However, despite abundant infiltrating T 
cells in the stroma of NPC, the development of tumor re-
mains progressive, suggesting that the immune responses 
against the cancerous cells may be down-regulated, per-
haps by cancer-derived immunosuppressive cytokines. 
Indeed, a previous study showed that an increased pro-
duction of interleukin-10 (IL-10) in the patients with NPC-
WHO type III or clinical late stage (6), suggesting that this 
cytokine may inhibit the functions of infiltrating T cell 
subsets in NPC tissues.  Therefore, the aim of the present 
study was to immunohistochemically determine the ex-
pression of CD4, CD8 and MHC class I in NPC tissues from 
Indonesian patients.
MATERIALS AND METHODS
NPC biopsies were obtained from 8 patients with nonke-
ratinizing carcinoma (WHO Type II) and 19 patients with 
undifferentiated carcinoma (WHO Type III).  The clinical 
staging of NPC was examined according to tumor-node-
metastasis (TNM) classification of the International 
Union Against Cancer rules for head and neck cancer. 
These NPC patients were then classified as early stage 
(stage I and II) and late stage (stage III and IV) as previ-
ously described (7).  Biopsies were collected from the 
patients undergone observations and treatments at the 
Dr. Sardjito’s General Hospital, Yogyakarta, Indonesia. 
All NPC patients were EBV positive by serological tests. 
The controls were derived from the nasopharyngeal tis-
sues of the EBV-seronegative subjects undergoing for the 
elective surgery. All participants and/or their relatives 
gave informed contents and this study was approved 
by the ethical committee of the Faculty of Medicine, 
Gadjah Mada University.
CD4+ and CD8+T cells as well as MHC class I positive 
cells in paraffin-embedded blocks were determined us-
ing the avidin-biotin-peroxidase complex.  Following cut 
and deparaffinization, the sections were blocked in 3% 
H2O2 dissolved in absolute methanol and then mounted 
with protein blocking agent (Lipshaw, Pittsburgh, PA). 
Biotinylated mouse anti-human CD4, CD8 and MHC class 
I antibodies (Sigma, St. Louis, MO) were applied on all 
sections which were then incubated for 30 minutes at 
room temperature.   After washing, all sections were re-
Epstein-Barr virus ilişkili  Nazofaringeal Karsinomada CD4, CD8 ve MHC Klas I Ekspresyonu: İmmunohistokimyasal 
Çalışma
Amaç: Epstein-Barr virus (EBV) ilişkili Nazofarengeal Karsinomun (NFK) immunopatogenezi tam olarak aydınlatılamamıştır. Bu 
çalışmanın amacı, NPC de CD4, CD8 ve MHC Klas I ekspresyonunun araştırmaktır
Metod: NFK tanılı ve kontrol gurubu olarak EBV seronegatif olan hastaların biyopsileri incelendi. Nasofarengial karsinom hastaları 
Dünya Sağlık Örgütü (WHO) NFK patolojik değerlendirme ve klinik evrelemesi kullanılarak sınıflandırıldı. Biyopsilerdeki CD4, CD8 
ve MHC Klas I ekspresyonu immunhistokimyasal olarak değerlendirildi.
Bulgular: CD4 pozitif, CD8 pozitif ve MHC Klas I pozitiflik miktarı NFK hücrelerinde EBV negatif guruba göre yüksek bulundu 
(p<0.05). WHO Tip 2 veya erken evre NFK daki pozitif hücre sayısı ile WHO Tip 3 veya geç evre arasında istatistiksel olarak fark yok-
tu (p>0.05). NFK hastalarında CD4 pozitif hücre sayısı ile CD8 pozitif hücre sayısı arasında istatistiksel olarak fark yoktu (p>0.05).
Sonuç: CD4, CD8 ve MHC Klas I moleküllerinin  ekspresyonunun NFK hastalarında patolojik sınıflandırma ve klinik evreleme 
ile alakalı olmadığını, nasofarenks karsinomunda CD4/CD8 oranı infiltre eden T hücre alt gurublarının fonksiyonunda azalma 
olduğuna işaret etmektedir.
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acted with the streptavidin-peroxidase (Lipshaw) for 30 
minutes, visualized using a 3-3’-diaminobenzidine tetra-
hydrochloride solution (DAB; Lipshaw) for 10-20 minutes 
and subsequently counterstained with hematoxylin. 
Cells with positive staining per mm2   were microscopi-
cally counted.
The data was statistically determined by a one way 
analysis of variance followed by Fischer’s least squared 
differences using a statistical package (SPSS Inc., 
Chicago).  
RESULTS
The positive staining for CD4+ and MHC class I+ cells 
were scattered in the stroma of NPC tissues (Figure 1). 
The distribution of these positive cells in NPC tissues 
with WHO II classification was almost similar with that 
in NPC tissues with WHO III. Statistically,  CD4+, CD8+ 
and MHC class I+ cells in cancerous tissues from NPC pa-
tients were higher than those from the healthy subject 
(p<0.05) (Figure 2 and 3). No statistically differences in 
the number of positive cells between WHO II and WHO III 
of NPC could be found (p>0.05) (Figure 1 and 2). When 
NPC patients were divided into clinical stages, the num-
ber of positive cells between early and late stage were 
not also significantly different (p>0.05) (Figure 3).  The 
number of CD4+ cells in each of pathological classifica-
tions and the clinical staging was not significantly differ-
ence with that of CD8+ cells (p>0.05) (Figure 2 and 3).
DISCUSSION
The present study showed that the number of infiltrating 
CD4+ cells in tissues from patients with NPC was signifi-
cantly higher than the control, suggesting that infiltrat-
ing CD4+ cells may play a role in the progression of NPC 
as also previously demonstrated (4,5). Interestingly, the 
present study indicated that the number of CD4+T cells 
was independent upon the pathological classification 
and clinical staging of NPC.   The exact reason to explain 
Figure 1. CD4, CD8 and MHC class I protein expression 
in nasopharyngeal carcinoma (NPC). Panel A, C and E 
are WHO Type II NPC, whereas panel B, D and F are 
WHO Type III. (A and B) = CD4 protein expression; (C 
and D)  = CD8 protein expression; (E and F) = MHC class 
I protein expression. Arrows indicate positive cells. 
(Original magnification X 400)  
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these results remains unclear. One of the possibilities is 
that CD4+T cells may be activated at the premalignant 
to malignant stage of EBV  infection; so that, the num-
ber of infiltrating CD4+ cells remains stable throughout 
the progression of NPC as previously suggested  (8,9). 
CD8 cells can be activated by EBV-derived antigens in 
a MHC class I-dependent mechanism (1). Therefore, in-
creased number of infiltrating cells CD8+ cells in NPC 
seen in the present study is not surprising and is sup-
ported by previous studies (5,10). Interestingly, the 
number of CD8+T cells in NPC biopsies as seen in the 
present study was not associated with the pathological 
classification and clinical staging of NPC. The exact rea-
son to explain these results is not clear, yet again. It is 
possible that the number CD8+T cells in the  late stage 
of NPC as seen in the present study might reflect a de-
fect of cell activation or functions in this clinical staging 
of this tumor (10,11), perhaps due to the action of IL-10 
(6,12), thereby inhibiting further proliferation and dif-
ferentiation of this T cell subset in NPC.   However, this 
notion needs to be further clarified. 
Of interest, the CD4+ and CD8+ cell ratio in all patho-
logical classifications and clinical stages of NPC seen in 
the present study was equal. In contrast, previous stud-
ies found that the number of infiltrating CD4+T cells in 
NPC is significantly higher that that of CD8+T cells (4,5). 
The exact reason to explain the discrepancy between 
the previous (5) and the present study is far from clear. 
Perhaps, this discrepancy may be due to different pa-
tient’s genetic background and/or EBV strains infected 
the NPC patients participated in the previous and the 
present study (1,2).     
NPC cells posse normal expression of essential compo-
nents, such as TAPs and LMP, of MHC class I processing 
pathway and hence, normal MHC class I-antigen pro-
cessing functions (13). Therefore, the results of present 
study showing that MHC class I expression in NPC was in-
creased as compared with the healthy control indicates 
that EBV infection may stimulate the synthesis of MHC 
class I molecules and antigen-presentation functions of 
NPC cells. Furthermore, the present study also demon-
strated that the expression of MHC class I in NPC is inde-
pendent on the clinical staging and pathological classifi-
cation of tumor and these results are in accordance with 
the previous study (5). One may assume, therefore, that 
MHC-class I-bearing NPC cells may present EBV-derived 
Figure 2. The number of CD4+, CD8+ and MHC class I+ 
cells in NPC tissues based on the WHO’s pathological 
classification. Bars represent mean and standard devia-
tion.  (*) = significant at p<0.05
Figure 3. The number of CD4+, CD8+ and MHC class I+ 
cells in NPC tissues based on the clinical staging. Bars 
represent mean and standard deviation.  (*) = signifi-
cant at p<0.05
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peptides to cytotoxic T cells at a similar magnitude in 
both early and late NPC stage or both non-keratinizing 
and undifferentiated NPC. 
In conclusion,  the results of the present study showed 
that the number of CD4+, CD8+ and MHC class I+ cells in 
the biopsies from NPC patients on Indonesia  was higher 
than that in the healthy control.  However, the number 
of these positive cells between WHO type II and III or 
between early and late clinical stage of NPC was not 
significantly differences. These results suggest, there-
fore, that the expression of CD4+, CD8+ and MHC class I 
may be increased in NPC but may not be associated with 
the pathological classification and clinical staging of this 
carcinoma in Indonesia. 
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